Patents by Inventor Bruce R. Conklin

Bruce R. Conklin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of determining cellular protein homeostasis
    Patent number: 11020463
    Abstract: The present invention provides assays and compositions to identify the risk of toxicity in a patient population with genotypic variations in specific proteins and/or protein complexes within the patient population.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: June 1, 2021
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Bruce R. Conklin, Luke Judge
  • METHOD OF DETERMINING CELLULAR PROTEIN HOMEOSTASIS
    Publication number: 20190015486
    Abstract: The present invention provides assays and compositions to identify the risk of toxicity in a patient population with genotypic variations in specific proteins and/or protein complexes within the patient population.
    Type: Application
    Filed: August 8, 2016
    Publication date: January 17, 2019
    Inventors: Bruce R. Conklin, Luke Judge
  • CELLS AND ASSAYS FOR USE IN DETECTING LONG QT SYNDROME
    Publication number: 20090227469
    Abstract: The present disclosure provides induced pluripotent stem (iPS) cells, and induced multipotent stem (iMS) cells, and progeny thereof, which cells include a gene encoding a polypeptide that regulates the QT interval. The present disclosure further provides panels of cardiomyocytes suitable for use in screening compounds for an effect on the QT interval. The cells and panels of cells can be used in a variety of applications, which are also provided.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 10, 2009
    Inventors: Bruce R. Conklin, Katriina Aalto-Setala
  • Selective target cell activation by expression of a G protein-coupled receptor activated superiorly by synthetic ligand
    Publication number: 20030167476
    Abstract: The invention provides a method for selectively activating a target cell, where the target cell expresses a receptor activated superiorly by a synthetic ligand (RASSL) having decreased binding affinity for a selected natural ligand and normal or near normal binding affinity for a synthetic small molecule agonist. Thus, RASSL-mediated activation of target cells does not occur to a significant extent in the presence of natural G protein-coupled receptor ligand, but is significantly stimulated upon exposure to a synthetic small molecule. RASSL-expressing target cells are selectively activated by exposing of the cells to an appropriate synthetic small molecule, which in turn binds the RASSL, resulting in G protein activation and triggering of a specific cellular response associated with G protein activation (e.g., cellular proliferation or cellular secretion).
    Type: Application
    Filed: December 12, 2002
    Publication date: September 4, 2003
    Inventor: Bruce R. Conklin
  • Selective target cell activation by expression of a G protein-coupled receptor activated superiorly by synthetic ligand
    Patent number: 6518480
    Abstract: The invention provides a method for selectively activating a target cell, where the target cell expresses a receptor activated superiorly by a synthetic ligand (RASSL) having decreased binding affinity for a selected natural ligand and normal or near normal binding affinity for a synthetic small molecule agonist. Thus, RASSL-mediated activation of target cells does not occur to a significant extent in the presence of natural G protein-coupled receptor ligand, but is significantly stimulated upon exposure to a synthetic small molecule. RASSL-expressing target cells are selectively activated by exposing of the cells to an appropriate synthetic small molecule, which in turn binds the RASSL, resulting in G protein activation and triggering of a specific cellular response associated with G protein activation (e.g., cellular proliferation or cellular secretion).
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: February 11, 2003
    Assignee: The Regents of the University of California
    Inventor: Bruce R. Conklin
  • Methods and compositions for identifying modulators of G-protein-coupled receptors
    Patent number: 6383761
    Abstract: The present invention provides methods and compositions that can be used to identify modulators of G-protein-coupled receptors.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: May 7, 2002
    Assignees: The Regents of the University of California, National Institutes of Health
    Inventors: Bruce R. Conklin, Evi Kostenis, Jürgen Wess
  • METHODS AND COMPOSITIONS FOR IDENTIFYING MODULATORS OF G-PROTEIN-COUPLED RECEPTORS
    Publication number: 20010053532
    Abstract: The present invention provides methods and compositions that can be used to identify modulators of G-protein-coupled receptors.
    Type: Application
    Filed: July 27, 1998
    Publication date: December 20, 2001
    Inventors: BRUCE R. CONKLIN, EVI KOSTENIS, JURGEN WESS